2 beaten-down stocks that still aren't worth buying

Your hard-earned money would be better spent elsewhere.

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...
Zacks Investment Research on MSN

Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving -3.13% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.28%. On ...

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...

Recursion Pharmaceuticals, Inc. Class A

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying

These aren't for the faint of heart.
The Motley Fool

Recursion Pharmaceuticals Is Going Big on AI. Here's Why It Could Be Worth Buying

Recursion's pitch to its customers, which are major biopharma companies, is that collaborating with it will reduce research and development (R&D) costs and timelines. To accomplish that, it employs a ...
American Association of Individual Investors

Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. Stock?

Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...